Peptides for Telehealth Operators: What You Need to Know
• The FDA's Bulks List explained — Category 1, 2, and 3, and what the reclassification of 14 peptides actually means for compounders
• The market opportunity: which patient populations are already seeking out peptides and which programs have natural demand
• What compliant compounding actually requires — beyond reclassification, including DMF filings and pharmaceutical-grade supply
• Clinical considerations for operators: prescribing criteria, patient selection, monitoring, and retention
Whether you're evaluating peptides for your program or trying to understand what building compliantly actually requires, this session will give you the clearest picture available right now.
The compliance infrastructure
serious telehealth brands build on.
Whether you're scaling an existing brand, or launching from scratch, CareValidate makes it easy.
